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DOUBLE-STRANDED PEPTIDE NUCLEIC 
ACIDS 
RELATED APPLICATION 
This patent application is related to the patent application 
entitled Higher Order Structure And Binding Of Peptide 
Nucleic Acids, U.S. Ser. No. 08/088,658, ?led Jul. 2, 1993. 
This patent application also is a continuation-in-part of 
patent application Ser. No. 08/054,363, ?led Apr. 26, 1993 
noW U.S. Pat. No. 5,539,082, Which is a continuation-in-part 
of application PCT EP92/01219, ?led May 22, 1992 and 
published Nov. 26, 1992 as WO 92/20702. The entire 
contents of each of the foregoing patent applications are 
incorporated herein by reference. 
FIELD OF THE INVENTION 
This invention is directed to generally linear compounds 
or “strands” Wherein naturally-occurring nucleobases or 
other nucleobase-binding moieties preferably are covalently 
bound to a polyamide backbone. In particular, the invention 
concerns compounds Wherein tWo such strands coordinate 
through hydrogen bonds to form a DNA-like double strand. 
BACKGROUND OF THE INVENTION 
The transcription and processing of genomic duplex DNA 
is controlled by generally proteinaceous transcription factors 
that recogniZe and bind to speci?c DNA sequences. One 
strategy for the control of gene expression is to add to a cell 
double-stranded DNA or double-stranded DNA-like struc 
tures that Will bind to the desired factor in preference to or 
in competition With genomic DNA, thereby inhibiting pro 
cessing of the DNA into a protein. This modulates the 
protein’s action Within the cell and can lead to bene?cial 
effects on cellular function. Naturally occurring or unmodi 
?ed oligonucleotides are unpractical for such use because 
they have short in vivo half-lives and they are poor cell 
membrane penetrators. 
These problems have resulted in an extensive search for 
improvements and alternatives. In order to improve half-life 
as Well as membrane penetration, a large number of varia 
tions in polynucleotide backbones has been undertaken. 
These variations include the use of methylphosphonates, 
phosphorothioates, phosphordithioates, phosphoramidates, 
phosphate esters, bridged phosphoroamidates, bridged 
phosphorothioates, bridged methylenephosphonates, 
dephospho internucleotide analogs With siloxane bridges, 
carbonate bridges, carboxymethyl ester bridges, acetamide 
bridges, carbamate bridges, thioether, sulfoxy, sulfono 
bridges, various “plastic” DNAs, ot-anomeric bridges, and 
borane derivatives. The great majority of these backbone 
modi?cations lead to decreased stability for hybrids formed 
betWeen the modi?ed oligonucleotide and its complemen 
tary native oligonucleotide, as assayed by measuring Tm 
values. 
Consequently, there remains a need in the art for stable 
compounds that can form double-stranded, helical structures 
mimicking double-stranded DNA. 
OBJECTS OF THE INVENTION 
It is one object of the present invention to provide 
compounds that mimic the double-helical structure of DNA. 
It is a further object of the invention to provide com 
pounds Wherein linear, polymeric strands coordinate 
through hydrogen bonds to form double helices. 
It is another object to provide compounds Wherein 
naturally-occurring nucleobases or other nucleobase 
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binding moieties are covalently bound to a non-sugar 
phosphate backbone. 
It is yet another object to provide therapeutic, diagnostic, 
and prophylactic methods that employ such compounds. 
SUMMARY OF THE INVENTION 
The present invention provides a novel class of 
compounds, knoWn as peptide nucleic acids (PNAs), that 
can coordinate With one another or With single-stranded 
DNA to form double-stranded (i.e., duplex) structures. The 
compounds include homopolymeric PNA strands and het 
eropolymeric PNA strands (e.g., DNA/PNA strands), Which 
coordinate through hydrogen bonding to form helical struc 
tures. Duplex structures can be formed, for example, 
betWeen tWo complementary PNA or PNA/DNA strands or 
betWeen tWo complementary regions Within a single such 
strand. 
In certain embodiments, each strand of the double 
stranded compounds of the invention includes a sequence of 
ligands covalently bound by linking moieties and at least 
one of said linking moieties comprising an amide, 
thioamide, sul?namide or sulfonamide linkage. The ligands 
on one strand hydrogen bond With ligands on the other 
strand and, together, assume a double helical structure. The 
compounds of the invention preferably comprise ligands 
linked to a polyamide backbone. Representative ligands 
include either the four main naturally occurring DNA bases 
(i.e., thymine, cytosine, adenine or guanine) or other natu 
rally occurring nucleobases (e.g., inosine, uracil, 
5-methylcytosine or thiouracil) or arti?cial bases (e.g., 
bromothymine, aZaadenines or aZaguanines, 
5-propynylthymine, etc.) attached to a peptide backbone 
through a suitable linker. These ligands are linked to the 
polyamide backbone through aZa nitrogen atoms or through 
amido and/or ureido tethers. 
In certain preferred embodiments, the peptide nucleic 
acids of the invention have the general formula (I): 
(I) 
wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroxy, (C1—C4)alkanoyl, 
naturally occurring nucleobases, non-naturally occur 
ring nucleobases, aromatic moieties, DNA 
intercalators, nucleobase-binding groups, heterocyclic 
moieties, and reporter ligands, at least one of L1—L” 
being a naturally occurring nucleobase, a non-naturally 
occurring nucleobase, a DNA intercalator, or a 
nucleobase-binding group; 
each of C1—C” is (CR6R7)y Where R6 is hydrogen and R7 
is selected from the group consisting of the side chains 
of naturally occurring alpha amino acids, or R6 and R7 
are independently selected from the group consisting of 
hydrogen, (C2—C6)alkyl, aryl, aralkyl, heteroaryl, 
hydroxy, (C1—C6)alkoxy, (C,—C6)alkylthio, NR3R4 and 
SR5, Where R3 and R4 are as de?ned above, and R5 is 
hydrogen, (C1—C6)alkyl, hydroxy-, alkoxy-, or 
alkylthio-substituted (C1—C6)alkyl, or R6 and R7 taken 
together complete an alicyclic or heterocyclic system; 
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each of D1—D” is (CRGR7 Z Where R6 and R7 are as de?ned 
above; 
each of y and Z is Zero or an integer from 1 to 10, the sum 
y+Z being greater than 2 but not more than 10; 
each of G1—G"_1 is —NR3CO—, —NR3CS—, 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
each pair of A1—A” and B1—B” are selected such that: 
(a) A is a group of formula (IIa), (IIb) or (11c) and B is 
(b) A is a group of formula (IId) and B is CH; 
W 
where: 
10 
15 
25 
30 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4; 
each ofp and q is Zero or an integer from 1 to 5, the sum 
p+q being not more than 10; 
each of r and s is Zero or an integer from 1 to 5, the sum 
r+s being not more than 10; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl Which may be 
hydroXy- or alkoXy- or alkylthio-substituted, hydroXy, 
alkoXy, alkylthio, amino and halogen; 
each of G1—G"_1 is —NR3CO—, —NR3CS—, 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
Q is —CO2H, —CONR‘R“, —SO3H or —SO2NR‘R“ or 
an activated derivative of —CO2H or —SO3H; and 
I is —NHR‘"R““ or —NR‘"C(O)R““, Where R‘, R“, R‘" 
and R““ are independently selected from the group 
consisting of hydrogen, alkyl, amino protecting groups, 
reporter ligands, intercalators, chelators, peptides, 
proteins, carbohydrates, lipids, steroids, nucleosides, 
nucleotides, nucleotide diphosphates, nucleotide 
triphosphates, oligonucleotides, oligonucleosides and 
soluble and non-soluble polymers. 
In certain embodiments, at least one A is a group of 
formula (11c) and B is N or R3N+. In other embodiments, A 
is a group of formula (Ila) or (IIb), B is N or R3N+, and at 
least one of y or Z is not 1 or 2. 
Preferred peptide nucleic acids have general formula 
(IIIa)—(IIIc): 
Rhw/(cHzh N 
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-continued 
L \ (i112) 
0 NR3 0 
O 
CH) Rh (CH2)k N ( 2”‘ (CH2)k \/ \N 
H 
7' 7' O R P R P 
n 
wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, heterocyclic moieties, natu 
rally occurring nucleobases, and non-naturally occur 
ring nucleobases; 
each R7’ is independently selected from the group con 
sisting of hydrogen and the side chains of naturally 
occurring alpha amino acids; 
n is an integer from 1 to 60; 
each of k, l, and m is independently Zero or an integer 
from 1 to 5; 
p is Zero or 1; 
Rh is OH, NH2 or —NHLysNH2; and 
Ri is H or COCH3. 
Particularly preferred are compounds having formula (IIIa) 
—(IIIc) Wherein each L is independently selected from the 
group consisting of the nucleobases thymine (T), adenine 
(A), cytosine (C), guanine (G) and uracil (U), k and m are 
Zero or 1, and n is an integer from 1 to 30, in particular from 
4 to 20. 
The peptide nucleic acids of the invention are synthesiZed 
by adaptation of standard peptide synthesis procedures, 
either in solution or on a solid phase. The synthons used are 
monomer amino acids or their activated derivatives, pro 
tected by standard protecting groups. The PNAs also can be 
synthesiZed by using the corresponding diacids and 
diamines. 
Thus, the novel monomer synthons according to the 
invention are selected from the group consisting of amino 
acids, diacids and diamines having general formulae: 
(IV) 
(V) 
(VI) 
Wherein L, A, B, C and D are as de?ned above, eXcept that 
any amino groups therein may be protected by amino 
(IIIc) 
L \(CH2)1 
NR3 
N (CHZ)HI 
\/ \ NH_Ri 
15 protecting groups; E is COOH, CSOH, SOOH, SOZOH or an 
20 
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activated derivative thereof; and F is NHR3 or NPgR3, 
Where R3 is as de?ned above and Pg is an amino protecting 
group. 
Preferred monomer synthons according to the invention 
have formula (VIIIa)—(VIIIc): 
(VIIIa) 
L 
O (CH2)1 
HO (CH2)k N (CH2)m \W \l/ \/ \NH2 
0 R7’ 
(VIIIb) 
L\ 
(CH2)1 
raw/k0 
HO (CH2Dk (CHZLI. \W \NH2 
0 R7’ P 
(VIIIc) 
L\ 
(CH2)1 
or amino-protected and/or acid terminal activated deriva 
tives thereof, Wherein L is selected from the group consisting 
of hydrogen, phenyl, heterocyclic moieties, naturally occur 
ring nucleobases, and non-naturally occurring nucleobases; 
and R7’ is selected from the group consisting of hydrogen 
and the side chains of naturally occurring alpha amino acids. 
These compounds are able to recogniZe one another to 
produce double helices. Such recognition can span 
sequences 5—60 base pairs long. Sequences betWeen 10 and 
20 bases are of interest since this is the range Within Which 
unique DNA sequences of prokaryotes and eukaryotes are 
found. Sequences betWeen 17—18 bases are of particular 
interest since this is the length of unique sequences in the 
human genome. 
Thus, in one aspect, the present invention provides meth 
ods for modulating the activity of a transcription factor in a 
cell, comprising the steps of forming a PNA-containing 
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double strand that binds the transcription factor and intro 
ducing the double strand into the cell. 
Further, the invention provides methods for modulating 
the activity of a protein in a cell, comprising the steps of 
forming a PNA-containing double strand that binds to or 
suppresses expression of the protein and introducing the 
double strand into the cell. 
The PNA duplex structures of the invention mimic 
dsDNA and can be used in diagnostics, therapeutics and as 
research reagents and kits. They can be used in pharmaceu 
tical compositions by including a suitable pharmaceutically 
acceptable diluent or carrier. 
BRIEF DESCRIPTION OF THE FIGURES 
The numerous objects and advantages of the present 
invention may be better understood by those skilled in the art 
by reference to the accompanying ?gures, in Which: 
FIG. 1 is a plot shoWing titration to saturation of a 10 mer 
PNA to a complementary 10 mer PNA. 
FIG. 2 is the development in time of the circular dichro 
ism signal of certain compounds of the invention. 
FIG. 3 is an Arrhenius plot of reaction rates at various 
temperatures during helical duplexation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As Will be recogniZed, a variety of double-stranded (i.e., 
duplex) PNA-containing structures can be prepared accord 
ing to the present invention. Representative duplexes can be 
formed Within a single homopolymeric PNA strand or a 
single heteropolymeric strand (e.g., a chimera PNA-DNA or 
PNA-RNA strand), or betWeen tWo homopolymeric PNA 
strands, tWo heteropolymeric PNA strands, or a homopoly 
meric PNA strand and a heteropolymeric PNA strand. 
Each PNA strand or PNA portion of a chimera strand 
preferably comprises a plurality of ligands, L, linked to a 
backbone via attachment at the position found in nature, i.e., 
position 9 for adenine or guanine, and position 1 for thymine 
or cytosine. Alternatively, L can be a non-naturally occurring 
nucleobase (nucleobase analog), another base-binding 
moiety, an aromatic moiety, (C1—C4)alkanoyl, hydroxy or 
even hydrogen. It Will be understood that the term nucleo 
base includes nucleobases bearing removable protecting 
groups. Some typical nucleobase ligands and illustrative 
synthetic ligands are shoWn in FIG. 2 of WO 92/20702. 
Furthermore, L can be a DNA intercalator, a reporter ligand 
such as, for example, a ?uorophor, radio label, spin label, 
hapten, or a protein-recogniZing ligand such as biotin. In 
monomer synthons, L can be blocked With protecting 
groups, as illustrated in FIG. 4 of WO 92/20702. 
Linker A can be a Wide variety of groups such as 
—CR1R2CO—, —CR1R2CS—, —CR1R2CSe—, 
—CR1R2CNHR2—, —CR1R2C=CH2— and 
—CR1R2C=C(CH3)2—, Where R1, R2 and R3 are as 
de?ned above. Preferably, A is methylenecarbonyl 
(—CH2CO—), amido (—CONR3—), or ureido 
(—NR3CONR3—). Also, A can be a longer chain moiety 
such as propanoyl, butanoyl or pentanoyl, or corresponding 
derivative, Wherein O is replaced by another value of X or 
the chain is substituted With RlR2 or is heterogenous, 
containing Y. Further, A can be a (C2—C6)alkylene chain, a 
(C2—C6)alkylene chain substituted With R‘lR2 or can be 
heterogenous, containing Y. In certain cases, A can just be a 
single bond. 
In one preferred form of the invention, B is a nitrogen 
atom, thereby presenting the possibility of an achiral back 
bone. B can also be R3N+, Where R3 is as de?ned above, or 
CH. 
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In the preferred form of the invention, C is —CR6R7—, 
but can also be a tWo carbon unit, i.e. —CHR6CHR7— or 
—CR6R7CH2—, Where R6 and R7 are as de?ned above. R6 
and R7 also can be a heteroaryl group such as, for example, 
pyrrolyl, furyl, thienyl, imidaZolyl, pyridyl, pyrimidinyl, 
indolyl, or can be taken together to complete an alicyclic 
system such as, for example, 1,2-cyclobutanediyl, 1,2 
cyclopentanediyl or 1,2-cyclohexanediyl. 
In a preferred form of the invention, E in the monomer 
synthon is COOH or an activated derivative thereof, and G 
in the oligomer is —CONR3—. As de?ned above, E also can 
be CSOH, SOOH, SO2OH or an activated derivative 
thereof, Whereby G in the oligomer becomes —CSNR3—, 
—SONR2— and —SO2NR3—, respectively. The activation 
can, for example, be achieved using an acid anhydride or an 
active ester derivative, Wherein hydrogen in the groups 
represented by E is replaced by a leaving group suited for 
generating the groWing backbone. 
The amino acids Which form the backbone can be iden 
tical or different. We have found that those based on 
2-aminoethylglycine are especially Well suited to the pur 
pose of the invention. 
In some cases it may be of interest to attach ligands at 
either terminus (Q, I) to modulate other properties of the 
PNAs. Representative ligands include DNA intercalators or 
basic groups, such as lysine or polylysine. Further groups 
such as carboxy and sulfo groups could also be used. The 
design of the synthons further alloWs such other moieties to 
be located on non-terminal positions. 
Duplexes according to the present invention can be 
assayed for their speci?c binding activity to a transcription 
factor. As used herein, the term “binding af?nity” refers to 
the ability of a duplex to bind to a transcription factor via 
hydrogen bonds, van der Waals interactions, hydrophobic 
interactions, or otherWise. For example a duplex can bind to 
a “leucine Zipper” transcription factor or a helix-loop-helix 
transcription factor via positively charged amino acids in 
one region of the transcription factor. 
Transcription factors, as the term is used herein, are DNA 
or RNA-binding proteins that regulate the expression of 
genes. HIV tat and c-rel are examples of transcription factors 
Which regulate the expression of genes. Also encompassed 
by the term are DNA and RNA binding proteins Which are 
not strictly considered transcription factors, but Which are 
knoWn to be involved in cell proliferation. These transcrip 
tion factors include c-myc, fos, and jun. Methods of the 
present invention are particularly suitable for use With 
transcription factor as target molecules since transcription 
factors generally occur in very small cellular quantities. 
The compounds of the present invention also may be 
useful to bind to other target molecules. Target molecules of 
the present invention can include any of a variety of bio 
logically signi?cant molecules. Such other target molecules 
can be nucleic acid strands such as signi?cant regions of 
DNA or RNA. Target molecules also can be carbohydrates, 
glycoproteins or other proteins. In some preferred embodi 
ments of the present invention, the target molecule is a 
protein such as an immunoglobulin, receptor, receptor bind 
ing ligand, antigen or enZyme and more speci?cally can be 
a phospholipase, tumor necrosis factor, endotoxin, 
interleukin, plasminogen activator, protein kinase, cell adhe 
sion molecule, lipoxygenase, hydrolase or transacylase. In 
other embodiments of the invention the target molecules can 
be important regions of the human immunode?ciency virus, 
Candida, herpes viruses, papillomaviruses, 
cytomegalovirus, rhinoviruses, hepatitises, or in?uenZa 
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viruses. In yet other embodiments of the present invention 
the target molecules can be regions of an oncogene. In still 
further embodiments, the target molecule is ras 47-mer stem 
loop RNA, the TAR element of human immunode?ciency 
virus or the gag-pol stem loop of human immunode?ciency 
virus (HIV). Still other targets can induce cellular activity. 
For example, a target can induce interferon. 
In binding to transcription factors or other target 
molecules, the transcription factor or other target molecule 
need not be puri?ed. It can be present, for example, in a 
Whole cell, in a humoral ?uid, in a crude cell lysate, in serum 
or in other humoral or cellular extract. Of course, puri?ed 
transcription factor or a puri?ed form of an other target 
molecule is also useful in some aspects of the invention. 
In still other embodiments of the present invention, syn 
thetically prepared transcription factor or other target mol 
ecule can be useful. A transcription factor or other target 
molecule also can be modi?ed, such as by biotinylation or 
radiolabeling. For example, synthetically prepared transcrip 
tion factor can incorporate one or more biotin molecules 
during synthesis or can be modi?ed post-synthesis. 
An illustrative series of PNA oligomers according to the 
invention can be prepared as described in Example 1 beloW 
and have been designed as folloWs: 
(1) Formulas 1 (SEQ ID NO:1) and 2 (SEQ ID NO:2), tWo 
complementary antiparallel PNA decamers that are not 
self-complementary: 
(aminoterminal) H-Gly-GTAGATCACT-LysNH2 1 
NH2Lys—CATCTAGTGA—GlyH (aminoterminal) 2 
(2) Formula 3 (SEQ ID NO:3), a single PNA oligomer 
possessing a self-complementary motif ten base pairs long 
With an intervening loop region containing ?ve base units: 
H- Gly- GTAGATCACT-TT 
T 
NH2Lys—CATCTAGTGA—TI‘ 
(3) Formula 4 (SEQ ID NO:4), a single PNA oligomer 
possessing a self complementary motif of ten base pairs long 
linked by an oligomethylene (n=1—10) spacer: 
H-GIyGTAGATCACT-(CHZ)11 
(4) Formula 5 (SEQ ID NO:5), a single PNA oligomer 
possessing a self-complementary motif ten base pairs long 
on one side interrupted by a three base bulge and an 
intervening loop region containing ?ve base units: 
TAT 
H- GlyGTAGAT CACT-TT 
T 
In each of the foregoing, NHZLys is intended to indicate that 
a lysine-amide is attached to the carboxyl end of the PNA. 
Use of such lysine-amide is not necessary; hoWever, its use 
is preferred since it is believed to suppress aggregation of the 
oligomers. The aminoterminal end of the PNA is substituted 
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With a glycine residue to avoid migration of the N-terminal 
nucleobase. The PNA amino-terminal and carboxy-terminal 
ends are intended to correspond, respectively, to the 5‘-ends 
and 3‘-ends of DNA. As a consequence of the designed 
sequences, these PNAs form duplexes having DNA-like 
antiparallel orientations. These PNAs additionally are 
capable of adopting a tertiary structure. 
As can be seen in FIG. 1, the circular dichroism (CD) of 
PNA 10-mers of Example 1 are almost vanishingly small, 
indicating that there is no preferred helical stacking of bases. 
HoWever, a strong CD spectrum arises upon titration of one 
10-mer With the complementary 10-mer, a saturation 
obtained at about 1:1 stoichiometry, as shoWn in FIG. 2. The 
CD spectrum resembles that of B-DNA, indicating a right 
handed helix. It is believed that a PNA-PNA complex having 
no preferred helicity initially is formed. The kinetics by 
Which this double-stranded structure reorganiZes into a 
uniform, right-handed double helix has been monitored and 
the activation parameters for the process determined. 
For DNA, circular dichroism in the nucleobase absorption 
region arises both from helical stacking of the bases, by 
excitation interactions betWeen the neighboring bases, and 
from interactions With transitions of the chiral riboses moi 
eties. In contrast, in PNA the electronic interaction betWeen 
most of the bases and the chiral terminal lysine is negligible 
and the main source of circular dichroism is attributable 
almost solely to the chiral orientation of the base-pairs 
relative to each other. The right-handed helicity observed for 
PNA is determined by the chiral bias of a terminal lysine 
residue. The formation of a helical duplex betWeen the tWo 
complementary PNA oligomers Was sloW enough to be 
folloWed by the increase in circular dichroism With time. 
This is in contrast With DNA-DNA duplex formation, Which 
occurs Within seconds. The development of circular dichro 
ism folloWs ?rst order reaction kinetics. Activation param 
eters have been determined by folloWing the association at 
various temperatures, as shoWn in FIG. 3. Control experi 
ments With different PNA concentrations gave identical 
results, con?rming that the PNA-PNA association is fast and 
includes a reorganiZation process in an already base-paired 
complex. This observation is further supported by the 
absence of time dependent hypochromicity in normal 
absorption spectra. Such a reorganiZation in the correspond 
ing cases of DNA-DNA and DNA-PNA decamers duplexes 
is too fast to be observed, indicating that the local chirality 
of the ribose in those cases immediately determines the 
handedness of base stacking. The conclusion is that the 
association of the tWo PNA-oligomers is fast in the base 
pairing ?rst step, but is folloWed by a sloW seeding of the 
duplex chirality, from the terminal lysine residue, toWards its 
right-handed helical structure. The activation energy 
obtained is 33.9 kJ/mole, Which is loW because the transition 
state is associated With a large negative entropy change 
(AS=—173 kJ/mole; see, e.g., FIG. 3), implying a highly 
ordered transition state. This is a strong indication that the 
rate-limiting inversion step is a cooperative seeding of 
chirality from the terminal base-pairs involving the entire 
stack of bases. 
We believe this is the ?rst time a pure cooperative 
inversion transition in a nucleic acid-like structure has been 
isolated. Also, in contrast to DNA Wherein ribose residues 
act as local chiral centers, optical activity of PNA-PNA 
duplexes is entirely a result of the helical arrangement of the 
nucleobases relative to each other. The CD spectrum can be 
compared With the theoretical and experimental spectra that 
have been generated for helix stacks of DNA bases to 
demonstrate the mimicry of DNA duplex structure. These 
US 6,228,982 B1 
11 
PNA-PNA duplexes therefore are useful mimics of DNA for 
the purpose of modulating the expression or transcription of 
DNA and thus modulating a disease state to the bene?t of a 
living organism. 
The utility of these PNA-containing duplex structures can 
be illustrated by constructing PNA sequences Which corre 
spond to various sequences of the HIV TAR element that 
have the potential to form duplex structures either as stem 
loop structures or tWo PNAs forming a duplex structure. In 
a competition assay, PNA structures that bind the tat tran 
scription factor prevent binding of the competitor TAR 
sequence present in the incubation mixture. As the TAR 
RNA sequence is biotinylated only tat proteins available to 
bind to TAR Will remain on the microtiter plate after 
Washing aWay unbound molecules and tat protein com 
plexed to a PNA sequence. The concentration dependence of 
the competition betWeen the TAR PNA structures and bioti 
nylated TAR structure Will serve to de?ne those sequences 
capable of effectively competing for tat and thus useful as 
HIV modulatory agents. 
Additional objects, advantages, and novel features of this 
invention Will become apparent to those skilled in the art 
upon examination of the folloWing examples thereof, Which 
are not intended to be limiting. 
EXAMPLE 1 
Synthesis of PNA Structures 
PNA having formulas 1 through 5 above are prepared 
generally according to the synthetic protocols described 
generally in Examples A, B and C and more particularly in 
Examples 11—127. Migration of the last nucleobase meth 
ylcarbonyl moiety to the terminal nitrogen is prevented by 
capping the N-terminus of the PNA chain With a glycine 
residue. The compounds are puri?ed by HPLC (reverse 
phase, 0.1% tri?uoroacetic acid in acetonitrile/Water) and 
the composition veri?ed by mass spectrometry. 
EXAMPLE 2 
Binding and Helix Formation of Complementary 
Antiparallel PNA Strands (FIG. 1) 
The circular dichroism spectra of PNA-PNA mixtures 
Were obtained by titrating PNA having sequence 
H-GTAGATCACT-LysNH2 (PNA formula 1 SEQ ID NO: 
1) With PNA having sequence H-AGTGATCTAC-LysNH2 
(PNA formula 2 SEQ ID NO: 2). The concentration of PNA 
formula 1 Was held constant (50 pmole/L) and the concen 
tration of PNA formula 2 Was increased to provide the 
folloWing formula 2:formula 1 stoichiometries: 0.25 (Curve 
C), 0.50 (Curve D), 0.75 (Curve E), 1.00 (Curve F), and 1.25 
(Curve G). The hybridiZations Were performed in a 5 
mmol/L sodium phosphate buffer, pH 7.0, at 20° C., after 20 
minutes of incubation. The path length Was 1 cm. Saturation 
Was obtained at equimolar amounts of the tWo decamers. 
FIG. 2 shoWs development of negative circular dichroism 
(at 220 nm) as a function of time after mixing equimolar 
amounts of PNA formula 1 With PNA formula 2. From top 
to bottom, the curves correspond to the folloWing tempera 
tures: 5° C., 15° C., 23° C., 32° C., 41° C., and 47° C. 
FIG. 3 shoWs an Arrhenius plot of rates from the CD 
kinetics. The plot provides the activation energy as AH=33.9 
kJ/mole (With the approximation that (kBT/h)exp(AS*/R) is 
constant). The full rate equation is k=(kBT/h)exp(—AH*)exp 
(ASi/R) then gives ASL-173 J/mole. 
EXAMPLE 3 
PNA Having Binding Af?nity for The HIV-tat 
Protein as Measured in a Competitive Inhibition 
Assay 
Samples of PNAs corresponding to various TAR 
sequences prepared by the method of Example 1 are incu 
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bated With recombinant tat transcription factor (100 pM) for 
15 minutes at room temperature at 1, 3, 10 ,30, and 100 pM 
(see, e.g., Cullen, et al., Cell 1990, 63, 655.). Acompetitor, 
a truncated version of the TAR sequence corresponding to 
residues 16—45 as a 2‘-O-methyl oligonucleotide, is 
employed as a TAR sequence and is biotinylated at the 3‘-O 
end by procedures generally in accordance With the proto 
cols of application Ser. No. 08/032,852, Combinatorial 
Oligomer Immunoabsorbant Screening Assay For Transcrip 
tion Factors And Other Biomolecule Binding, ?led Mar. 16, 
1993, the entire contents of Which are incorporated herein by 
reference. This TAR sequence is added at 100 nM concen 
tration. The reaction is incubated for 20 minutes and then 
added to streptavidin-coated microtiter plate Wells. After 
unbound molecules are Washed aWay With phosphate 
buffered saline (PBS), 100 pL of 1:500 tat antisera is added 
to each Well and incubated for 2 hours. Protein A/G antisera 
phosphatase is bound to the tat antibodies and PNPP 
(p-nitrophenylphosphate) substrate (200 pl) then is added. 
Color development is measured 2 hours later by reading 
absorbance at 405 nM on a Titertek Multiscan ELISA plate 
reader. 
EXAMPLE 4 
PNA Having Binding Af?nity for the C-myc 
Protein 
Myc-c is a nuclear protein involved in cell proliferation, 
differentiation, and neoplastic disease and binds DNA in a 
sequence speci?c manner. See, e.g., Nissen, Cancer 
Research 1986, 46, 6217 and BlackWell, Science 1990, 250, 
1149. Crude nuclear extracts of myc-c are prepared gener 
ally in accordance With FranZa, et al., Nature 1987, 330, 391, 
from HL 60 cells stimulated to induce the expression of 
myc-c. 
Phosphorothioate oligonucleotides having the sequences 
GAT CCC CCC ACC ACG TGG TGC CTG A-B (SEQ ID 
N016) and GAT CTC AGG CAC CAC GTG GTG GGG 
G-B (SEQ ID NO:7), Where B=biotin, are synthesiZed on an 
automated DNA synthesiZer (Applied Biosystems model 
380B) using modi?ed standard phosphoramidite chemistry 
With oxidation by a 0.2M solution of 3H-1,2-benZodithiole 
3-one 1,1-dioxide in acetonitrile for stepWise thiation of 
phosphite linkages. The thiation cycle Wait step is 68 sec 
onds and is folloWed by the capping step. 
[3-Cyanoethyldiisopropyl phosphoramidites can be pur 
chased from Applied Biosystems (Foster City, Calif.). Bases 
are deprotected by incubation in methanolic ammonia over 
night. FolloWing base deprotection, the oligonucleotides are 
dried in vacuo. Removal of 2‘-hydroxyl t-butyldimethylsilyl 
protecting groups is effected by incubating the oligonucle 
otide in 1M tetrabutylammonium ?uoride in tetrahydrofuran 
overnight. The RNA oligonucleotides are further puri?ed on 
C18 Sep-Pak cartridges (Waters, Division of Millipore 
Corp., Milford, Mass.) and ethanol precipitated. The phos 
phorothioate oligonucleotides are hybridiZed to create the 
double stranded NF-kB binding site. 
Aseries of PNA-PNA duplexes is synthesiZed and hybrid 
iZed to give a neW series of PNA duplexes corresponding to 
different length portions of the myc-c binding sequence. 
Each duplex is incubated in triplicate at concentrations of 1, 
3, 10, 30, and 100 pM With the HL-60 extract described 
above. The myc P=S binding site then is added and the 
mixtures are incubated and Washed With PBS. An antibody 
directed to the leucine Zipper region of the myc protein 
(Santa CruZ Biotechnology) is added at a 1:1000 dilution. 
Non-bound molecules are Washed aWay With PBS. Binding 
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of myc to biotinylated c-myc transcription factor is quanti 
tated by adding 100 pl of 1:500 tat antisera to each Well for 
2 hours. Protein A/G-alkaline phosphatase (Pierce; 15000; 
100 pl) then is added and any excess is removed by Washing 
With PBS. PNPP substrate (200 pl) then is added. Color 
development is measured 2 hours later by reading absor 
bance at 405 nM on a Titertek Multiscan ELISAplate reader. 
EXAMPLE 5 
PNA Having Binding Af?nity for the C-rel 
Transcription Factor 
C-rel has been shoWn to represent a constituent of the 
NF-kB site binding transcription factor, Which plays a 
crucial role in the expression of a number of genes including 
the immunoglobulin k light chain gene, IL-2ra, and MHC. 
(see, e.g., Gilmore, et al., Cell 1986, 62, 791.) 
Crude nuclear extracts are prepared as detailed by Emma, 
et al., Nature 1987, 330, 391, from Jurkat cells stimulated 4 
hours With 1 pM PHA and 100 nM PMA to induce the 
expression of rel. The extract is then preabsorbed With 100 
pl streptavidin agarose per ml for 10 minutes. This is 
folloWed With the addition of poly dI.dC as a nonspeci?c 
competitor at a concentration of 100 pig/ml of extract. 
Nuclear extracts containing the biotinylated NF-kB binding 
site competitor are prepared as in Example 4, above. 
Aseries of PNA duplexes is synthesiZed to correspond to 
various length fragments of the consensus binding sequence 
of c-rel. NF-kB binding site competitor is added to each 
duplex and the resulting samples are Washed. Antibody 
directed to rel is added. The amount of rel bound is quan 
titated by adding 100 pl of 1:500 rel antisera to each Well for 
2 hours. Protein A/G-alkaline phosphatase (Pierce; 15000; 
100 pl) the is added and any excess is removed by Washing 
With PBS. PNPP substrate (200 pl) then is added. Color 
development is measured 2 hours later by reading absor 
bance at 405 nM on a Titertek Multiscan ELISAplate reader. 
EXAMPLE 6 
PNA Having Binding Af?nity for the AP-1 
Transcription Factor 
Genes belonging to the fos and jun oncogene families 
encode nuclear proteins associated With a number of tran 
scriptional complexes, see, e.g., Konig, et al., EMBO Jour 
nal 1989, 8, 2559. C-jun is a major component of the AP-1 
binding site, Which Was originally shoWn to regulate tissue 
plasminogen activator (TPA) induced expression of respon 
sive genes through the TPA response element (TRE). The 
jun protein forms homo- or heterodimers Which bind the 
TRE. The fos protein is only active as a heterodimer With 
any of the jun family of proteins. Fos/jun heterodimers have 
a much higher affinity for the TRE than jun homodimers. 
Both the fos and the jun cDNA have been cloned doWn 
stream of the Sp6 promoter. RNA is produced from each 
plasmid in vitro, then used to produce functional jun and fos 
proteins in rabbit reticulocyte lystates. The fos and jun 
proteins are then alloWed to bind to the biotinylated AP-1 
binding site in competition With PNA duplex sequences 
constructed as mimics of the proper consensus sequence for 
binding fos and jun, CGC TTG GTG ACT CAG CCG GAA 
(SEQ ID NO: 8). Binding is quantitated With an antibody 
directed to fos or jun. When the fos alone is incubated With 
the AP-1 site there Will be no detectable binding With either 
antibody. When the jun alone is incubated With the binding 
site, a signal Will be detected With only the jun antibody. This 
10 
15 
20 
30 
35 
40 
45 
50 
55 
60 
65 
14 
is consistent With the formation of a jun homodimer, Which 
has previously been demonstrated to bind AP-1. When the 
fos and jun proteins are mixed a signal Will be detected With 
both fos and jun antibodies. This is consistent With the 
formation of a fos/jun homodimer Which is knoWn to bind 
the AP-1 site and should be detectable With either antibody. 
PNA sequences of the present invention can be tested for 
the ability to block the formation of the fos/jun heterodimer. 
Molecules Which block formation Will decrease the signal 
detected With the fos antibody, but not the jun antibody. 
EXAMPLE 7 
Chimera Macromolecule Having Peptide Nucleic 
Acids Section Attaching to 3‘ Terminus of a 2‘ 
Deoxy Phosphorothioate Oligonucleotide Section 
A ?rst section of peptide nucleic acids is prepared as per 
PCT patent application WO 92/20702. The peptide nucleic 
acids are prepared from the C terminus toWards the N 
terminus using monomers having protected amino groups. 
FolloWing completion of the peptide region, the terminal 
amine blocking group is removed and the resulting amine 
reacted With a 3‘-C-(formyl)-2‘, 3‘-dideoxy-5‘-trityl nucle 
otide as prepared per the procedure of Vasseur, et. al., J. Am. 
Chem. Soc. 1992, 114, 4006. The condensation of the amine 
With the aldehyde moiety of the C-formyl nucleoside is 
effected as per the conditions of the Vasseur, ibid., to yield 
an intermediate imine linkage. The imine linkage is reduced 
under reductive the alkylation conditions of Vasseur, ibid., 
With HCHO/NaBH3CN/AcOH to yield the nucleoside con 
nected to the peptide nucleic acid via an methyl alkylated 
amine linkage. An internal 2‘-deoxy phosphorothioate nucle 
otide region is then continued from this nucleoside as per 
standard automatated DNA synthetic protocols (see Oligo 
nucleotide synthesis, a practic approach, M. J. Gait ed, IRL 
Press, 1984). 
EXAMPLE 8 
Chimera Macromolecule Having Peptide Nucleic 
Acids Section Attaching to 5‘ Terminus of a 
Phosphorothioate Oligonucleotide Section 
A phosphorothioate oligonucleotide is prepared in the 
standard manner on a solid support as per standard protocols 
(see Oligonucleotides and Analogues, A Practical Approach, 
F. Eckstein Ed., IRL Press, 1991. The dimethoxytrityl block 
ing group on that nucleotide is removed in the standard 
manner. Peptide synthesis for the peptide region is com 
menced by reaction of the carboxyl end of the ?rst peptide 
nucleic acid of this region With the 5‘ hydroxy of the last 
nucleotide of the DNA region. Coupling is effected via EDC 
(Pierce) in pyridine to form an ester linkage betWeen the 
peptide and the nucleoside. Peptide synthesis is then con 
tinued in the manner of patent application WO 92/20702 to 
complete the peptide nucleic acid region. 
EXAMPLE 9 
Double Stranded Structures that Include Chimera 
Strand 
Duplex structures Will be formed With the chimera strands 
of Examples 7 and 8. Duplex structures can include duplexes 
betWeen a PNA-RNA or PNA-DNA strand and a RNA 
strand, a PNA-RNA or PNA-DNA strand and a DNA strand, 
a PNA-RNA or PNA-DNA strand and a PNA strand or a 
PNA-RNA or PNA-DNA strand and a further chimeric 
PNA-DNA or PNA-RNA strand. 
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EXAMPLE 10 
Binding Between PNA Containing Double Stranded 
Structure and Transcription Factor or Other Protein 
A double stranded PNA structure, a structure containing 
PNA chimeric strand and a nucleic acid strand or tWo PNA 
chimera strands Will be used to bind to or otherWise modu 
late single stranded DNA, double stranded DNA, RNA, a 
transcription factor or other protein. In the use of a PNA 
containing chimera, part of the binding betWeen the chimera 
and the transcription factor or other protein can include 
binding betWeen the sugar-phosphate backbone of the DNA 
or RNA portion of the chimera and hydrogen bonding 
betWeen the ligands, e.g. nucleobases, of the PNAportion of 
the chimera. Binding to the sugar-phosphate backbone 
includes binding to phosphodiester linkages, phosphorothio 
ate linkages or other linkgages that may be used as the 
backbone of the DNA or RNA. In other instances, bonding 
can include hydrophobic contacts betWeen hydrophobic 
groups on the ligands, including nucleobases, of the PNA or 
the nucleobases of the nucleic acid portion of the chimera 
With like hydrophobic groups on proteins that are being 
bound. Such hydrophobic groups on the chimeric strand 
include the methyl groups on thymine nucleobases. 
Those skilled in the art Will appreciate that numerous 
changes and modi?cations can be made to the preferred 
embodiments of the invention and that such changes and 
modi?cations can be made Without departing from the spirit 
of the invention. It is therefore intended that the appended 
claims cover all such equivalent variations as fall Within the 
true spirit and scope of the invention. 
EXAMPLE A 
Synthesis of PNA Oligomers and Polymers 
The principle of anchoring molecules onto a solid matrix, 
Which helps in accounting for intermediate products during 
chemical transformations, is knoWn as Solid-Phase Synthe 
sis or Merri?eld Synthesis (see, e.g., Merri?eld, J. Am. 
Chem. Soc., 1963, 85, 2149 and Science, 1986, 232, 341). 
Established methods for the stepWise or fragmentWise solid 
phase assembly of amino acids into peptides normally 
employ a beaded matrix of slightly cross-linked styrene 
divinylbenZene copolymer, the cross-linked copolymer hav 
ing been formed by the pearl polymeriZation of styrene 
monomer to Which has been added a mixture of divinylben 
Zenes. A level of 1—2% cross-linking is usually employed. 
Such a matrix also can be used in solid-phase PNA synthesis 
in accordance With the present invention (FIG. 4). 
Concerning the initial functionaliZation of the solid phase, 
more than ?fty methods have been described in connection 
With traditional solid-phase peptide synthesis (see, e.g., 
Barany and Merri?eld in “The Peptides” Vol. 2, Academic 
Press, NeW York, 1979, pp. 1—284, and SteWart and Young, 
“Solid Phase Peptide Synthesis”, 2nd Ed., Pierce Chemical 
Company, 111., 1984). Reactions for the introduction of 
chloromethyl functionality (Merri?eld resin; via a chlorom 
ethyl methyl ether/SnCl4 reaction), aminomethyl function 
ality (via an N-hydroxymethylphthalimide reaction; see, 
Mitchell, et al., Tetrahedron Lett., 1976, 3795), and benZhy 
drylamino functionality (Pietta, et al., J. Chem. Soc., 1970, 
650) are the most Widely applied. Regardless of its nature, 
the purpose of the functionality is normally to form an 
anchoring linkage betWeen the copolymer solid support and 
the C-terminus of the ?rst amino acid to be coupled to the 
solid support. As Will be recogniZed, anchoring linkages also 
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can be formed betWeen the solid support and the amino acid 
N-terminus. It is generally convenient to express the “con 
centration” of a functional group in terms of millimoles per 
gram (mmol/g). Other reactive functionalities Which have 
been initially introduced include 4-methylbenZhydrylamino 
and 4-methoxybenZhydrylamino. All of these established 
methods are in principle useful Within the context of the 
present invention. Preferred methods for PNA synthesis 
employ aminomethyl as the initial functionality, in that 
aminomethyl is particularly advantageous With respect to the 
incorporation of “spacer” or “handle” groups, oWing to the 
reactivity of the amino group of the aminomethyl function 
ality With respect to the essentially quantitative formation of 
amide bonds to a carboxylic acid group at one end of the 
spacer-forming reagent. Avast number of relevant spacer- or 
handle-forming bifunctional reagents have been described 
(see, Barany, et al., Int. J. Peptide Protein Res., 1987, 30, 
705), especially reagents Which are reactive toWards amino 
groups such as found in the aminomethyl function. Repre 
sentative bifunctional reagents include 4-(haloalkyl)aryl 
loWer alkanoic acids such as 4-(bromomethyl)phenylacetic 
acid, Boc-aminoacyl-4-(oxymethyl)aryl-loWer alkanoic 
acids such as Boc-aminoacyl-4-(oxymethyl)phenylacetic 
acid, N-Boc-p-acylbenZhydrylamines such as N-Boc-p 
glutaroylbenZhydrylamine, N-Boc-4‘-loWer alkyl-p 
acylbenZhydrylamines such as N-Boc-4‘-methyl-p 
glutaroylbenZhydrylamine, N-Boc-4‘-loWer alkoxy-p 
acylbenZhydrylamines such as N-Boc-4‘-methoxy-p 
glutaroyl-benZhydrylamine, and 
4-hydroxymethylphenoxyacetic acid. One type of spacer 
group particularly relevant Within the context of the present 
invention is the phenylacetamidomethyl (Pam) handle 
(Mitchell and Merri?eld, J. Org. Chem., 1976, 41, 2015) 
Which, deriving from the electron WithdraWing effect of the 
4-phenylacetamidomethyl group, is about 100 times more 
stable than the classical benZyl ester linkage toWards the 
Boc-amino deprotection reagent tri?uoroacetic acid 
Certain functionalities (e.g., benZhydrylamino, 
4-methylbenZhydrylamino and 
4-methoxybenZhydrylamino) Which may be incorporated for 
the purpose of cleavage of a synthesiZed PNA chain from the 
solid support such that the C-terminal of the PNA chain is in 
amide form, require no introduction of a spacer group. Any 
such functionality may advantageously be employed in the 
context of the present invention. 
An alternative strategy concerning the introduction of 
spacer or handle groups is the so-called “preformed handle” 
strategy (see, Tam, et al., Synthesis, 1979, 955—957), Which 
offers complete control over coupling of the ?rst amino acid, 
and excludes the possibility of complications arising from 
the presence of undesired functional groups not related to 
the peptide or PNA synthesis. In this strategy, spacer or 
handle groups, of the same type as described above, are 
reacted With the ?rst amino acid desired to be bound to the 
solid support, the amino acid being N-protected and option 
ally protected at the other side-chains Which are not relevant 
With respect to the groWth of the desired PNA chain. Thus, 
in those cases in Which a spacer or handle group is desirable, 
the ?rst amino acid to be coupled to the solid support can 
either be coupled to the free reactive end of a spacer group 
Which has been bound to the initially introduced function 
ality (for example, an aminomethyl group) or can be reacted 
With the spacer-forming reagent. The space-forming reagent 
is then reacted With the initially introduced functionality. 
Other useful anchoring schemes include the “multidetach 
able” resins (Tam, et al., Tetrahedron Lett., 1979, 4935 and 
J. Am. Chem. Soc, 1980, 102, 611; Tam, J. Org. Chem., 
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1985, 50, 5291), Which provide more than one mode of 
release and thereby allow more ?exibility in synthetic 
design. 
Suitable choices for N-protection are the tert 
butyloXycarbonyl (Boc) group (Carpino,J. Am. Chem. Soc., 
1957, 79, 4427; McKay, et al.,J. Am. Chem. Soc., 1957, 79, 
4686; Anderson, et al., J. Am. Chem. Soc., 1957, 79, 6180) 
normally in combination With benZyl-based groups for the 
protection of side chains, and the 
9-?uorenylmethyloXycarbonyl (Fmoc) group (Carpino, et 
al., J. Am. Chem. Soc., 1970, 92, 5748 and J. Org. Chem., 
1972, 37, 3404), normally in combination With tert-butyl 
(tBu) for the protection of any side chains, although a 
number of other possibilities eXist Which are Well knoWn in 
conventional solid-phase peptide synthesis. Thus, a Wide 
range of other useful amino protecting groups eXist, some of 
Which are Adoc (Hass, et al., J. Am. Chem. Soc., 1966, 88, 
1988), Bpoc (Sieber,Helv. Chem.Acta., 1968, 51, 614), Mcb 
(Brady, et al., J. Org. Chem., 1977, 42, 143), Bic (Kemp, et 
al., Tetrahedron, 1975, 4624), the o-nitrophenylsulfenyl 
(Nps) (Zervas, et al., J. Am. Chem. Soc., 1963, 85, 3660), 
and the dithiasuccinoyl (Dts) (Barany, et al., J. Am. Chem. 
Soc., 1977, 99, 7363). These amino protecting groups, 
particularly those based on the Widely-used urethane 
functionality, successfully prohibit racemiZation (mediated 
by tautomeriZation of the readily formed oXaZolinone 
(aZlactone) intermediates (Goodman, et al., J. Am. Chem. 
Soc., 1964, 86, 2918)) during the coupling of most ot-amino 
acids. In addition to such amino protecting groups, a Whole 
range of otherWise “Worthless” nonurethane-type of amino 
protecting groups are applicable When assembling PNA 
molecules, especially those built from achiral units. Thus, 
not only the above-mentioned amino protecting groups (or 
those derived from any of these groups) are useful Within the 
conteXt of the present invention, but virtually any amino 
protecting group Which largely ful?lls the folloWing require 
ments: (1) stability to mild acids (not signi?cantly attacked 
by carboXyl groups); (2) stability to mild bases or nucleo 
philes (not signi?cantly attacked by the amino group in 
question); (3) resistance to acylation (not signi?cantly 
attacked by activated amino acids). Additionally: (4) the 
protecting group must be close to quantitatively removable, 
Without serious side reactions, and (5) the optical integrity, 
if any, of the incoming amino acid should preferably be 
highly preserved upon coupling. Finally, the choice of 
side-chain protecting groups, in general, depends on the 
choice of the amino protecting group, since the protection of 
side-chain functionalities must Withstand the conditions of 
the repeated amino deprotection cycles. This is true Whether 
the overall strategy for chemically assembling PNA mol 
ecules relies on, for example, differential acid stability of 
amino and side-chain protecting groups (such as is the case 
for the above-mentioned “Boc-benZyl” approach) or 
employs an orthogonal, that is, chemoselective, protection 
scheme (such as is the case for the above-mentioned “Fmoc 
tBu” approach), 
FolloWing coupling of the ?rst amino acid, the neXt stage 
of solid-phase synthesis is the systematic elaboration of the 
desired PNA chain. This elaboration involves repeated 
deprotection/coupling cycles. The temporary protecting 
group, such as a Boc or Fmoc group, on the last-coupled 
amino acid is quantitatively removed by a suitable 
treatment, for example, by acidolysis, such as With tri?uo 
roacetic acid, in the case of Boc, or by base treatment, such 
as With piperidine, in the case of Fmoc, so as to liberate the 
N-terminal amine function. 
The neXt desired N-protected amino acid is then coupled 
to the N-terminal of the last-coupled amino acid. This 
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coupling of the C-terminal of an amino acid With the 
N-terminal of the last-coupled amino acid can be achieved 
in several Ways. For eXample, it can be bound by providing 
the incoming amino acid in a form With the carboXyl group 
activated by any of several methods, including the initial 
formation of an active ester derivative such as a 2,4,5 
trichlorophenyl ester (Pless, et al., Helv. Chim. Acta, 1963, 
46, 1609), a phthalimido ester (Nefkens, et al.,J. Am. Chem. 
Soc., 1961, 83, 1263), a pentachlorophenyl ester 
(KuprysZeWski, Rocz. Chem., 1961, 35, 595), a penta?uo 
rophenyl ester (Kovacs, et al., J. Am. Chem. Soc., 1963, 85, 
183), an o-nitrophenyl ester (BodanZsky, Nature, 1955, 175, 
685), an imidaZole ester (Li, et al.,J. Am. Chem. Soc., 1970, 
92, 7608), and a 3-hydroXy-4-oXo-3,4-dihydroquinaZoline 
(Dhbt-OH) ester (Konig, et al., Chem. Ber, 1973, 103, 2024 
and 2034), or the initial formation of an anhydride such as 
a symmetrical anhydride (Wieland, et al.,Angew. Chem., Int. 
Ed. EngL, 1971, 10, 336). Alternatively, the carboXyl group 
of the incoming amino acid can be reacted directly With the 
N-terminal of the last-coupled amino acid With the assis 
tance of a condensation reagent such as, for eXample, 
dicycloheXylcarbodiimide (Sheehan, et al., J. Am. Chem. 
Soc., 1955, 77, 1067) or derivatives thereof. BenZotriaZolyl 
N-oXy-trisdimethylaminophosphonium heXa?uorophos 
phate (BOP), “Castro’s reagent” (see, e.g., Rivaille, et al., 
Tetrahedron, 1980, 36, 3413) is recommended When assem 
bling PNA molecules containing secondary amino groups. 
Finally, activated PNA monomers analogous to the recently 
reported amino acid ?uorides (Carpino, J. Am. Chem. Soc., 
1990, 112, 9651) hold considerable promise to be used in 
PNA synthesis as Well. 
FolloWing assembly of the desired PNA chain, including 
protecting groups, the neXt step Will normally be deprotec 
tion of the amino acid moieties of the PNA chain and 
cleavage of the synthesiZed PNA from the solid support. 
These processes can take place substantially simultaneously, 
thereby providing the free PNA molecule in the desired 
form. Alternatively, in cases in Which condensation of tWo 
separately synthesiZed PNA chains is to be carried out, it is 
possible by choosing a suitable spacer group at the start of 
the synthesis to cleave the desired PNA chains from their 
respective solid supports (both peptide chains still incorpo 
rating their side-chain protecting groups) and ?nally remov 
ing the side-chain protecting groups after, for eXample, 
coupling the tWo side-chain protected peptide chains to form 
a longer PNA chain. 
In the above-mentioned “Boc-benZyl” protection scheme, 
the ?nal deprotection of side-chains and release of the PNA 
molecule from the solid support is most often carried out by 
the use of strong acids such as anhydrous HF (Sakakibara, 
et al., Bull. Chem. Soc. Jpn., 1965, 38, 4921), boron tris 
(tri?uoroacetate) (Pless, et al., Helv. Chim. Acta, 1973, 46, 
1609), and sulfonic acids such as tri?uoromethanesulfonic 
acid and methanesulfonic acid (Yajima, et al.,J. Chem. Soc., 
Chem. C0mm., 1974, 107). This conventional strong acid 
(e.g., anhydrous HF) deprotection method, produces very 
reactive carbocations that may lead to alkylation and acy 
lation of sensitive residues in the PNA chain. Such side 
reactions are only partly avoided by the presence of scav 
engers such as anisole, phenol, dimethyl sul?de, and 
mercaptoethanol and, therefore, the sul?de-assisted acidol 
ytic SN2 deprotection method (Tam, et al., J. Am. Chem. 
Soc., 1983, 105, 6442 and J. Am. Chem. Soc., 1986, 108, 
5242), the so-called “loW”, Which removes the precursors of 
harmful carbocations to form inert sulfonium salts, is fre 
quently employed in peptide and PNA synthesis, either 
solely or in combination With “high” methods. Less 
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frequently, in special cases, other methods used for depro 
tection and/or ?nal cleavage of the PNA-solid support bond 
are, for example, such methods as base-catalyZed alcoholy 
sis (Barton, et al., J. Am. Chem. Soc., 1973, 95, 4501), and 
ammonolysis as Well as hydraZinolysis (BodansZky, et al., 
Chem. Ind., 1964 1423), hydrogenolysis (Jones, Tetrahedron 
Lett. 1977 2853 and Schlatter, et al., Tetrahedron Lett. 1977 
2861)), and photolysis (Rich and GurWara, J. Am. Chem. 
Soc., 1975 97, 1575)). 
Finally, in contrast With the chemical synthesis of “nor 
mal” peptides, stepWise chain building of achiral PNAs such 
as those based on aminoethylglycyl backbone units can start 
either from the N-terminus or the C-terminus, because the 
coupling reactions are free of racemiZation. Those skilled in 
the art Will recogniZe that Whereas syntheses commencing at 
the C-terminus typically employ protected amine groups and 
free or activated acid groups, syntheses commencing at the 
N-terminus typically employ protected acid groups and free 
or activated amine groups. 
Based on the recognition that most operations are iden 
tical in the synthetic cycles of solid-phase peptide synthesis 
(as is also the case for solid-phase PNA synthesis), a neW 
matrix, PEPS, Was recently introduced (Berg, et al., J. Am. 
Chem. Soc., 1989, 111, 8024 and International Patent Appli 
cation WO 90/02749) to facilitate the preparation of large 
numbers of peptides. This matrix is comprised of a poly 
ethylene (PE) ?lm With pendant long-chain polystyrene (PS) 
grafts (molecular Weight on the order of 106). The loading 
capacity of the ?lm is as high as that of a beaded matrix, but 
PEPS has the additional ?exibility to suit multiple syntheses 
simultaneously. Thus, in a neW con?guration for solid-phase 
peptide synthesis, the PEPS ?lm is fashioned in the form of 
discrete, labeled sheets, each serving as an individual com 
partment. During all the identical steps of the synthetic 
cycles, the sheets are kept together in a single reaction vessel 
to permit concurrent preparation of a multitude of peptides 
at a rate close to that of a single peptide by conventional 
methods. It Was reasoned that the PEPS ?lm support, 
comprising linker or spacer groups adapted to the particular 
chemistry in question, should be particularly valuable in the 
synthesis of multiple PNA molecules, these being concep 
tually simple to synthesiZe since only four different reaction 
compartments are normally required, one for each of the 
four “pseudo-nucleotide” units. Thus, the PEPS ?lm support 
has been successfully tested in a number of PNA syntheses 
carried out in a parallel and substantially simultaneous 
fashion. The yield and quality of the products obtained from 
PEPS Were comparable to those obtained by using the 
traditional polystyrene beaded support. Also, experiments 
With other geometries of the PEPS polymer such as, for 
example, non-Woven felt, knitted net, sticks or microWell 
plates have not indicated any limitations of the synthetic 
ef?cacy. 
TWo other methods proposed for the simultaneous syn 
thesis of large numbers of peptides also apply to the prepa 
ration of multiple, different PNA molecules. The ?rst of 
these methods (Geysen, et al., Proc. Natl. Acad. Sci. USA, 
1984, 81, 3998) utiliZes acrylic acid-grafted polyethylene 
rods and 96-microtiter Wells to immobiliZe the groWing 
peptide chains and to perform the compartmentaliZed syn 
thesis. While highly effective, the method is only applicable 
on a microgram scale. The second method (Houghten, Proc. 
Natl. Acad. Sci. USA, 1985, 82, 5131) utiliZes a “tea bag” 
containing traditionally-used polymer beads. Other relevant 
proposals for multiple peptide or PNA synthesis in the 
context of the present invention include the simultaneous 
use of tWo different supports With different densities 
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(Tregear, in “Chemistry and Biology of Peptides”, J. 
Meienhofer, ed., Ann Arbor Sci. Publ., Ann Arbor, 1972 pp. 
175—178), combining of reaction vessels via a manifold 
(Gorman, Anal. Biochem., 1984, 136, 397), multicolumn 
solid-phase synthesis (e.g. Krchnak, et al., Int. J. Peptide 
Protein Res., 1989, 33, 209), and Holm and Meldal, in 
“Proceedings of the 20th European Peptide Symposium”, G. 
Jung and E. Bayer, eds., Walter de Gruyter & Co., Berlin, 
1989 pp. 208—210), and the use of cellulose paper (Eichler, 
et al., Collect. Czech. Chem. Commun., 1989, 54, 1746). 
While the conventional cross-linked styrene/ 
divinylbenZene copolymer matrix and the PEPS support are 
presently preferred in the context of solid-phase PNA 
synthesis, a non-limiting list of examples of solid supports 
Which may be of relevance are: (1) Particles based upon 
copolymers of dimethylacrylamide cross-linked With N,N‘ 
bisacryloylethylenediamine, including a knoWn amount of 
N-tertbutoxycarbonyl-beta-alanyl-N‘ 
acryloylhexamethylenediamine. Several spacer molecules 
are typically added via the beta alanyl group, folloWed 
thereafter by the amino acid residue subunits. Also, the beta 
alanyl-containing monomer can be replaced With an acryloyl 
sarcosine monomer during polymeriZation to form resin 
beads. The polymeriZation is folloWed by reaction of the 
beads With ethylenediamine to form resin particles that 
contain primary amines as the covalently linked function 
ality. The polyacrylamide-based supports are relatively more 
hydrophilic than are the polystyrene-based supports and are 
usually used With polar aprotic solvents including 
dimethylformamide, dimethylacetamide, 
N-methylpyrrolidone and the like (see Atherton, et al., J. 
Am. Chem. Soc., 1975, 97, 6584, Bioorg. Chem. 1979, 8, 
351), and J. C. S. Perkin I 538 (1981)); (2) a second group 
of solid supports is based on silica-containing particles such 
as porous glass beads and silica gel. One example is the 
reaction product of trichloro-[3-(4-chloromethyl)phenyl] 
propylsilane and porous glass beads (see Parr and 
Grohmann,Angew. Chem. Internal. Ed. 1972, 11, 314) sold 
under the trademark “PORASIL E” by Waters Associates, 
Framingham, Mass., USA. Similarly, a mono ester of 1,4 
dihydroxymethylbenZene and silica (sold under the trade 
mark “BIOPAK” by Waters Associates) has been reported to 
be useful (see Bayer and Jung, Tetrahedron Lett., 1970, 
4503); (3) a third general type of useful solid supports can 
be termed composites in that they contain tWo major ingre 
dients: a resin and another material that is also substantially 
inert to the organic synthesis reaction conditions employed. 
One exemplary composite (see Scott, et al., J. Chrom. Sci., 
1971, 9, 577) utiliZed glass particles coated With a 
hydrophobic, cross-linked styrene polymer containing reac 
tive chloromethyl groups, and Was supplied by Northgate 
Laboratories, Inc., of Hamden, Conn., USA. Another exem 
plary composite contains a core of ?uorinated ethylene 
polymer onto Which has been grafted polystyrene (see Kent 
and Merri?eld, Israel J. Chem. 1978, 17, 243) and van 
Rietschoten in “Peptides 1974”, Y. Wolman, Ed., Wiley and 
Sons, NeW York, 1975, pp. 113—116); and (4) contiguous 
solid supports other than PEPS, such as cotton sheets (Lebl 
and Eichler, Peptide Res. 1989, 2, 232) and 
hydroxypropylacrylate-coated polypropylene membranes 
(Daniels, et al., Tetrahedron Lett. 1989, 4345), are suited for 
PNA synthesis as Well. 
Whether manually or automatically operated, solid-phase 
PNA synthesis in the context of the present invention is 
normally performed batchWise. HoWever, most of the syn 
theses may equally Well be carried out in the continuous 
?oW mode, Where the support is packed into columns 
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(Bayer, et al., Tetrahedron Lett., 1970, 4503 and Scott, et al., 
J. Chromatogr. Sci., 1971, 9, 577). With respect to 
continuous-?oW solid-phase synthesis, the rigid poly 
(dimethylacrylamide)-Kieselguhr support (Atherton, et al., 
J. Chem. Soc. Chem. Commun., 1981, 1151) appears to be 
particularly successful, but another valuable con?guration 
concerns the one Worked out for the standard copoly 
(styrene-1%-divinylbenZene) support (Krchnak, et al., Tet 
rahedron Lett., 1987, 4469). 
While the solid-phase technique is presently preferred in 
the context of PNA synthesis, other methodologies or com 
binations thereof, for example, in combination With the 
solid-phase technique, apply as Well: (1) the classical 
solution-phase methods for peptide synthesis (e.g., 
BodansZky, “Principles of Peptide Synthesis”, Springer 
Verlag, Berlin-New York 1984), either by stepWise assembly 
or by segment/fragment condensation, are of particular 
relevance When considering especially large scale produc 
tions (gram, kilogram, and even tons) of PNA compounds; 
(2) the so-called “liquid-phase” strategy, Which utiliZes 
soluble polymeric supports such as linear polystyrene 
(Shemyakin, et al., Tetrahedron Lett., 1965, 2323) and 
polyethylene glycol (PEG) (Mutter and Bayer, Angew. 
Chem., Int. Ed. Engl, 1974, 13, 88), is useful; (3) random 
polymeriZation (see, e.g., Odian, “Principles of 
Polymerization”, McGraW-Hill, NeW York (1970)) yielding 
mixtures of many molecular Weights (“polydisperse”) pep 
tide or PNA molecules are particularly relevant for purposes 
such as screening for antiviral effects; (4) a technique based 
on the use of polymer-supported amino acid active esters 
(Fridkin, et al., J. Am. Chem. Soc., 1965, 87, 4646), some 
times referred to as “inverse Merri?eld synthesis” or “poly 
meric reagent synthesis”, offers the advantage of isolation 
and puri?cation of intermediate products, and may thus 
provide a particularly suitable method for the synthesis of 
medium-sized, optionally protected, PNA molecules, that 
can subsequently be used for fragment condensation into 
larger PNA molecules; (5) it is envisaged that PNA mol 
ecules may be assembled enZymatically by enZymes such as 
proteases or derivatives thereof With novel speci?cities 
(obtained, for example, by arti?cial means such as protein 
engineering). Also, one can envision the development of 
“PNA ligases” for the condensation of a number of PNA 
fragments into very large PNA molecules; (6) since anti 
bodies can be generated to virtually any molecule of interest, 
the recently developed catalytic antibodies (abZymes), dis 
covered simultaneously by the groups of Lerner 
(Tramantano, et al., Science, 1986, 234, 1566) and of 
SchultZ (Pollack, et al., Science, 1986, 234, 1570), should 
also be considered as potential candidates for assembling 
PNA molecules. Thus, there has been considerable success 
in producing abZymes catalyZing acyl-transfer reactions (see 
for example Shokat, et al., Nature, 1989, 338, 269) and 
references therein). Finally, completely arti?cial enZymes, 
very recently pioneered by SteWart’s group (Hahn, et al., 
Science, 1990, 248, 1544), may be developed to suit PNA 
synthesis. The design of generally applicable enZymes, 
ligases, and catalytic antibodies, capable of mediating spe 
ci?c coupling reactions, should be more readily achieved for 
PNA synthesis than for “normal” peptide synthesis since 
PNA molecules Will often be comprised of only four differ 
ent amino acids (one for each of the four native nucleobases) 
as compared to the tWenty natural by occurring 
(proteinogenic) amino acids constituting peptides. In 
conclusion, no single strategy may be Wholly suitable for the 
synthesis of a speci?c PNA molecule, and therefore, some 
times a combination of methods may Work best. 
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EXAMPLE B 
Synthesis of Monomeric Building Blocks 
The monomers preferably are synthesiZed by the general 
scheme outlined in FIG. 5. This involves preparation of 
either the methyl or ethyl ester of (Bocaminoethyl)glycine, 
by a protection/deprotection procedure as described in 
Examples 34—36. The synthesis of thymine monomer is 
described in Examples 37—38, and that of the protected 
cytosine monomer is described in Example 39. 
The synthesis of the protected adenine monomer (FIG. 6) 
involved alkylation With ethyl bromoacetate (Example 40) 
and veri?cation of the position of substitution by X-ray 
crystallography, as being the Wanted 9-position. The 
N6-amino group then Was protected With the benZyloxycar 
bonyl group by the use of the reagent N-ethyl 
benZyloxycarbonylimidaZole tetra?uoroborate (Example 
41). Simple hydrolysis of the product ester (Example 42) 
gave N6-benZyloxycarbonyl-9-carboxymethyl adenine, 
Which then Was used in the standard procedure (Examples 
43—44, FIG. 5). The adenine monomer has been built into 
tWo different PNA-oligomers (Examples 66, 67, 81 and 83). 
The synthesis of the protected G-monomer is outlined in 
FIG. 7. The starting material, 2-amino-6-chloropurine, Was 
alkylated With bromoacetic acid (Example 45) and the 
chlorine atom Was then substituted With a benZyloxy group 
(Example 46). The resulting acid Was coupled to the 
(bocaminoethyl) glycine methyl ester (from Example 46) 
With agent PyBrop TM, and the resulting ester Was hydrolysed 
(Example 47). The O6-benZyl group Was removed in the 
?nal HF-cleavage step in the synthesis of the PNA-oligomer. 
Cleavage Was veri?ed by ?nding the expected mass of the 
?nal PNA-oligomer, upon incorporation into an PNA 
oligomer using diisopropyl carbodiimide as the condensa 
tion agent (Examples 65 and 81). 
EXAMPLE C 
Extended Backbones 
Alterations of the groups A, C and D (FIG. 16) is 
demonstrated by the synthesis of monomeric building 
blocks and incorporation into PNA-oligomers. 
In one example, the C group Was a CH(CH3) group. The 
synthesis of the corresponding monomer is outlined in FIG. 
8. It involves preparation of Boc-protected 1-amino-2,3 
propanediol (Example 48), Which is cleaved by periodate to 
give bocaminoacetaldehyde, Which is used directly in the 
next reaction. The bocaminoacetaldehyde can be condensed 
With a variety of amines; in Example 49, alanine ethyl ester 
Was used. In Examples 50—52, the corresponding thymine 
monomers Were prepared. The monomer has been incorpo 
rated into an 8-mer (Example 70) by the DCC-coupling 
protocol (Examples 66 and 67). 
In another example, the D group is a (CH2)3 group. The 
synthesis of the corresponding monomer is outlined in FIG. 
ISA and described in Examples 53—54. 
In another example, the A group is a (CH2)2CO group. 
The synthesis of the corresponding thymine monomer is 
outlined FIG. 18.B and Examples 56 through 58. 
In yet another example, the C group is a (CH2)2 group. 
The synthesis of the thymine and protected cytosine mono 
mer is outlined in FIG. 9 and Examples 59 through 64. 
Hybridization experiments With a PNA-oligomer containing 
one unit is described in Examples 71 and 91, Which shoWs 
a signi?cant loWering of af?nity but a retention of speci?c 
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GENERAL REMARKS 
The following abbreviations are used in the experimental 
examples: DMF, N,N-dimethylformamide; DCC, N,N 
dicyclohexyl carbodiimide; DCU, N,N-dicyclohexyl urea; 
THF, tetrahydrofuran; aeg, N-acetyl (2‘-aminoethyl)glycine; 
pfp, penta?uorophenyl; Boc, tert-butoxycarbonyl; Z, ben 
Zyloxycarbonyl; NMR, nuclear magnetic resonance; s, sin 
glet; d, doublet; dd, doublet of doublets; t; triplet; q, quartet; 
m, multiplet; b, broad; 6, chemical shift; 
NMR spectra Were recorded on either a JEOL FX 90Q 
spectrometer, or a Bruker 250 MHZ With tetramethylsilane 
as internal standard. Mass spectrometry Was performed on a 
MassLab VG 12-250 quadropole instrument ?tted With a VG 
FAB source and probe. Melting points Were recorded on 
Buchi melting point apparatus and are uncorrected. N,N 
Dimethylformamide Was dried over 4 A molecular sieves, 
distilled and stored over 4 A molecular sieves. Pyridine 
(HPLC quality) Was dried and stored over 4 A molecular 
sieves. Other solvents used Were either the highest quality 
obtainable or Were distilled before use. Dioxane Was passed 
through basic alumina prior to use. Bocanhydride, 
4-nitrophenol, methyl bromoacetate, benZyloxycarbonyl 
chloride, penta?uorophenol Were all obtained through Ald 
rich Chemical Company. Thymine, cytosine, adenine Were 
all obtained through Sigma. 
Thin layer chromatography (Tlc) Was performed using the 
folloWing solvent systems: (1) chloroform:triethyl 
amine:methanol, 7:1:2; (2) methylene chloride:methanol, 
9:1; (3) chloroform:methanol:acetic acid 85:10:5. Spots 
Were visualiZed by UV (254 nm) or/and spraying With a 
ninhydrin solution (3 g ninhydrin in 1000 ml 1-butanol and 
30 ml acetic acid), after heating at 120° C. for 5 min and, 
after spraying, heating again. 
EXAMPLE 11 
tert-Butyl 4-nitrophenyl carbonate 
Sodium carbonate (29.14 g; 0.275 mol) and 4-nitrophenol 
(12.75 g; 91.6 mmol) Were mixed With dioxane (250 ml). 
Boc-anhydride (20.0 g; 91.6 mmol) Was transferred to the 
mixture With dioxane (50 ml). The mixture Was re?uxed for 
1 h, cooled to 00 C., ?ltered and concentrated to 1/3, and then 
poured into Water (350 ml) at 0° C. After stirring for 1/2 h., 
the product Was collected by ?ltration, Washed With Water, 
and then dried over sicapent, in vacuo. Yield 21.3 g (97%). 
M.p. 73.0—74.5° C. (litt. 78.5—79.5° C.). Anal. for 
C11H13NO5 found(calc.) C: 55.20(55.23) H: 5.61(5.48) N: 
5 .82(5 .85). 
EXAMPLE 12 
(N‘-Boc-2‘-aminoethyl) glycine (2) 
The title compound Was prepared by a modi?cation of the 
procedure by Heimer, et al. Int. J. Pept. , 1984, 23, 203—211 
N-(2-Aminoethyl)glycine (1, 3.00 g; 25.4 mmol) Was dis 
solved in Water (50 ml), dioxane (50 ml) Was added, and the 
pH Was adjusted to 11.2 With 2 N sodium hydroxide. 
tert-Butyl-4-nitrophenyl carbonate (7.29 g; 30.5 mmol) Was 
dissolved in dioxane (40 ml) and added dropWise over a 
period of 2 h, during Which time the pH Was maintained at 
11.2 With 2 N sodium hydroxide. The pH Was adjusted 
periodically to 11.2 for three more hours and then the 
solution Was left overnight. The solution Was cooled to 0° C. 
and the pH Was carefully adjusted to 3.5 With 0.5 M 
hydrochloric acid. The aqueous solution Was Washed With 
chloroform (3><200 ml), the pH adjusted to 9.5 With 2N 
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sodium hydroxide and the solution Was evaporated to 
dryness, in vacuo (14 mmHg). The residue Was extracted 
With DMF (25+2><10 ml) and the extracts ?ltered to remove 
excess salt. This results in a solution of the title compound 
in about 60% yield and greater than 95% purity by tlc 
(system 1 and visualised With ninhydrin, Rf=0.3). The 
solution Was used in the folloWing preparations of Boc-aeg 
derivates Without further puri?cation. 
EXAMPLE 13 
N-1-Carboxymethylthymine (4) 
This procedure is different from the literature synthesis, 
but is easier, gives higher yields, and leaves no unreacted 
thymine in the product. To a suspension of thymine (3, 40.0 
g; 0.317 mol) and potassium carbonate (87.7 g; 0.634 mmol) 
in DMF (900 ml) Was added methyl bromoacetate (30.00 ml; 
0.317 mmol). The mixture Was stirred vigorously overnight 
under nitrogen. The mixure Was ?ltered and evaporated to 
dryness, in vacuo. The solid residue Was treated With Water 
(300 ml) and 4 N hydrochloric acid (12 ml), stirred for 15 
min at 0° C., ?ltered, and Washed With Water (2><75 ml). The 
precipitate Was treated With Water (120 ml) and 2N sodium 
hydroxide (60 ml), and Was boiled for 10 minutes. The 
mixture Was cooled to 0° C., ?ltered, and the pure title 
compound Was precipitated by the addition of 4 N hydro 
chloric acid (70 ml). Yield after drying, in vacuo over 
sicapent: 37.1 g (64%). 1H-NMR: (90 MHZ; DMSO-dG): 
11.33 ppm (s,1H,NH); 7.49(d,J=0.92 HZ,1H,ArH); 4.38 
(s,2H,CH2); 1.76 (d,J=0.92 HAT-CH3) 
EXAMPLE 14 
N-1-Carboxymethylthymine penta?uorophenyl ester 
5 
N-1-Carboxymethylthymine (4, 10.0 g; 54.3 mmol) and 
penta?uorophenol (10.0 g; 54.3 mmol) Were dissolved in 
DMF (100 ml) and cooled to 5° C. in ice Water. DCC (13.45 
g; 65.2 mmol) then Was added. When the temperature passed 
beloW 5° C., the ice bath Was removed and the mixture Was 
stirred for 3 h at ambient temperature. The precipitated DCU 
Was removed by ?ltration and Washed tWice With DMF 
(2><10 ml). The combined ?ltrate Was poured into ether 
(1400 ml) and cooled to 0° C. Petroleum ether (1400 ml) 
Was added and the mixture Was left overnight. The title 
compound Was isolated by ?ltration and Was Washed thor 
oughly With petroleum ether. Yield: 14.8 g (78%). The 
product Was pure enough to carry out the next reaction, but 
an analytical sample Was obtained by recrystalliZation from 
2-propanol. M.p. 200.5—206° C. Anal. for C13H7F5N2O4. 
Found(calc.) C: 44.79(44.59); H: 2.14(2.01) N: 8.13(8.00). 
FAB-MS: 443 (M+1+glycerol), 351 (M+1). 1H-NMR (90 
MHZ; DMS-d6): 11.52 ppm (s,1H,NH) ; 7.64 (s,1H,ArH); 
4.99 (s,2H, CH2); 1.76 (s,3H,CH3). 
EXAMPLE 15 
1-(Boc-aeg)thymine (6) 
To the DMF-solution from above Was added triethyl 
amine (7.08 ml; 50.8 mmol) folloWed by N-1 
carboxymethylthymine penta?uorophenyl ester (5, 4.45 g; 
12.7 mmol). The resultant solution Was stirred for 1 h. The 
solution Was cooled to 0° C. and treated With cation 
exchange material (“DoWex 50W X-8”, 40 g) for 20 min. 
The cation exchange material Was removed by ?ltration, 
Washed With dichloromethane (2><15 ml), and dichlo 
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romethane (150 ml) Was added. The resulting solution Was 
Washed With saturated sodium chloride, dried over magne 
sium sulfate, and evaporated to dryness, in vacuo, ?rst by a 
Water aspirator and then by an oil pump. The residue Was 
shaken With Water (50 ml) and evaporated to dryness. This 
procedure Was repeated once. The residue then Was dis 
solved in methanol (75 ml) and poured into ether (600 ml) 
and petroleum ether (1.4 L). After stirring overnight, the 
White solid Was isolated by ?ltration and Was Washed With 
petroleum ether. Drying over sicapent, in vacuo, gave 3.50 
g (71.7%). M.p. 142—147° C. Anal. for C16H24N4O7. Found 
(calc.) C: 49.59(50.00) H: 6.34(6.29) N: 14.58(14.58). 
1H-NMR (250 MHZ, DMSO-dG): Due to the limited rotation 
around the secondary amide bond several of the signals Were 
doubled in the ratio 2: 1,(indicated in the list by mj. for major 
and mi. for minor). 12.73 ppm (b,1H, —CO2H); 11.27 ppm 
(s, mj., imide); 11.25 ppm (s, mi., imide); 7.30 ppm (s, mj., 
ArH); 7.26 ppm (s, mi., ArH); 6.92 ppm (unres. t, mj., 
BocNH); 6.73 ppm (unres. t; mi., BocNH); 4.64 ppm (s, mj., 
T—CH2—CO—); 4.47 ppm (s, mi., T—CH2—CO—); 4.19 
ppm (s, mi., CONRCHZCOZH); 3.97 ppm (s, mj., CONRC 
HZCOZH); 3.41—2.89 ppm (unres. m, —CH2CH2— and 
Water); 1.75 ppm (s,3H, T—CH3); 1.38 ppm (s, 9H, t-Bu). 
13C-NMR: 170.68 ppm (CO); 170.34 (CO); 167.47 (CO); 
167.08 (CO); 164.29 (CO); 150.9 (C5“); 141.92 (C6“); 
108.04 (C2‘); 77.95 and 77.68 (Thy-CHZCO); 48.96, 47.45 
and 46.70 (—QH2QH2— and NCHZCOZH); 37.98 (Thy-C 
H3); 28.07 (t-Bu). FAB-MS: 407 (M+Na”); 385 (M+H”). 
EXAMPLE 16 
1-(Boc-aeg)thymine penta?uorophenyl ester (7, 
Boc-Ta-eg.OPfp) 
1-(Boc-aeg)thymine (6) (2.00 g; 5.20 mmol) Was dis 
solved in DMF (5 ml) and methylene chloride (15 ml) Was 
added. Penta?uorophenol (1.05 g; 5.72 mmol) Was added 
and the solution Was cooled to 00 C. in an ice bath. DDC then 
Was added (1.29 g; 6.24 mmol) and the ice bath Was 
removed after 2 min. After 3 h With stirring at ambient 
temperature, the precipitated DCU Was removed by ?ltration 
and Washed With methylene chloride. The combined ?ltrate 
Was Washed tWice With aqueous sodium hydrogen carbonate 
and once With saturated sodium chloride, dried over mag 
nesium sulfate, and evaporated to dryness, in vacuo. The 
solid residue Was dissolved in dioxane (150 ml) and poured 
into Water (200 ml) at 0° C. The title compound Was isolated 
by ?ltration, Washed With Water, and dried over sicapent, in 
vacuo. Yield: 2.20 g (77%). An analytical sample Was 
obtained by recrystallisation from 2-propanol. M.p. 
174—175.5° C. Analysis for C22H23N4O7F5, found(calc.): C: 
48.22(48.01); H: 4.64(4.21); N: 9.67(10.18). 1H-NMR (250 
MHZ, CDCl3): Due to the limited rotation around the 
secondary amide bond several of the signals Were doubled in 
the ratio 6:1 (indicated in the list by mj. for major and mi. 
for minor). 7.01 ppm (s, mi., ArH); 6.99 ppm (s, mj., ArH); 
5.27 ppm (unres. t, BocNH); 4.67 ppm (s, mj., T—CH2— 
CO—); 4.60 ppm (s, mi., T—CH2—CO—); 4.45 ppm (s, 
mj., CONRCHZCOZPfp); 4.42 ppm (s, mi., CONRC 
HZCOZPfp); 3.64 ppm (t,2H,BocNHCH2CH2—); 3.87 ppm 
(“q”,2H,BocNHCH2CH2—); 1.44(s,9H,t-Bu). FAB-MS: 
551 (10; M+1); 495 (10; M+1-tBu); 451 (80; -Boc). 
EXAMPLE 17 
N4-BenZyloxycarbonyl cytosine (9) 
Over a period of about 1 h, benZyloxycarbonyl chloride 
(52 ml; 0.36 mol) Was added dropWise to a suspension of 
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cytosine (8, 20.0 g;0.18 mol) in dry pyridine (1000 ml) at 0° 
C. under nitrogen in oven-dried equipment. The solution 
then Was stirred overnight, after Which the pyridine suspen 
sion Was evaporated to dryness, in vacuo. Water (200 ml) 
and 4 N hydrochloric acid Were added to reach pH ~1. The 
resulting White precipitate Was ?ltered off, Washed With 
Water and partially dried by air suction. The still-Wet pre 
cipitate Was boiled With absolute ethanol (500 ml) for 10 
min, cooled to 0° C., ?ltered, Washed thoroughly With ether, 
and dried, in vacuo. Yield 24.7 g (54%). M.p.>250° C. Anal. 
for C12H11N3O3. Found(calc.); C: 58.59(58.77); H: 4.55 
(4.52); N: 17.17(17.13). No NMR spectra Were recorded 
since it Was not possible to get the product dissolved. 
EXAMPLE 18 
N4-BenZyloxycarbonyl-N1-carboxymethyl cytosine 
(10) 
In a three necked round bottomed ?ask equipped With 
mechanical stirring and nitrogen coverage Was placed 
methyl bromacetate (7.82 ml;82.6 mmol) and a suspension 
of N4-benZyloxycarbonyl-cytosine (9, 21.0 g; 82.6 mmol) 
and potassium carbonate (11.4 g; 82.6 mmol) in dry DMF 
(900 ml). The mixture Was stirred vigorously overnight, 
?ltered, and evaporated to dryness, in vacuo. Water (300 ml) 
and 4 N hydrochloric acid (10 ml) Were added, the mixture 
Was stirred for 15 minutes at 0° C., ?ltered, and Washed With 
Water (2><75 ml). The isolated precipitate Was treated With 
Water (120 ml), 2N sodium hydroxide (60 ml), stirred for 30 
min, ?ltered, cooled to 0° C., and 4 N hydrochloric acid (35 
ml) Was added. The title compound Was isolated by 
?ltration, Washed thoroughly With Water, recrystalliZed from 
methanol (1000 ml) and Washed thoroughly With ether. This 
afforded 7.70 g (31%) of pure compound. The mother liquor 
from the recrystalliZation Was reduced to a volume of 200 ml 
and cooled to 0° C. This afforded an additional 2.30 g of a 
material that Was pure by tlc but had a reddish color. M.p. 
266—274° C. Anal. for C14H13N3O5. Found(calc.); C: 55.41 
(55.45); H: 4.23(4.32); N: 14.04(13.86). 1H-NMR (90 MHZ; 
DMSO-dG): 8.02 ppm (d,J=7.32 HZ,1H,H-6); 7.39 (s,5H, 
Ph) 7.01 (d,J=7.32 HZ,1H, H-5); 5.19 (s,2H,PhCH2—); 4.52 
(s,2H). 
EXAMPLE 19 
N4-BenZyloxycarbonyl-N1-carboxymethyl-cytosine 
penta?uorophenyl ester (11) 
N4-BenZyloxycarbonyl-N-carboxymethyl-cytosine (10, 
4.00 g; 13.2 mmol) and penta?uorophenol (2.67 g; 14.5 
mmol) Were mixed With DMF (70 ml), cooled to 0° C. With 
ice-Water, and DCC (3.27 g; 15.8 mmol) Was added. The ice 
bath Was removed after 3 min and the mixture Was stirred for 
3 h at room temperature. The precipitated DCU Was 
removed by ?ltration, Washed With DMF, and the ?ltrate Was 
evaporated to dryness, in vacuo (0.2 mmHg). The solid 
residue Was treated With methylene chloride (250 ml), stirred 
vigorously for 15 min, ?ltered, Washed tWice With diluted 
sodium hydrogen carbonate and once With saturated sodium 
chloride, dried over magnesium sulfate, and evaporated to 
dryness, in vacuo. The solid residue Was recrystalliZed from 
2-propanol (150 ml) and the crystals Were Washed thor 
oughly With ether. Yield 3.40 g (55%). M.p. 241—245° C. 
Anal. for C2OH12N3F5O5. Found(calc.); C: 51.56(51.18); H: 
2.77(2.58); N: 9.24(8.95).1H-NMR (90 MHZ; CDCl3): 7.66 
ppm (d,J=7.63 HZ,1H,H-6); 7.37 (s,5H,Ph); 7.31 (d,J=7.63 
HZ,1H,H-5); 5.21 (s,2H,PhCH2—); 4.97 (s,2H,NCH2—). 
FAB-MS: 470 (M+1) 
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EXAMPLE 20 
N4-BenZyloxycarbonyl-1-Boc-aeg-cytosine (12) 
To a solution of (N-Boc-2-aminoethyl)glycine (2) in 
DMF, prepared as described above, Was added triethyl 
amine (7.00 ml; 50.8 mmol) and N4-benZyloxycarbonyl-N1 
carboxymethyl-cytosine penta?uorophenyl ester (11, 2.70 g; 
5.75 mmol). After stirring the solution for 1 h at room 
temperature, methylene chloride (150 ml), saturated sodium 
chloride (250 ml), and 4 N hydrochloric acid to pH ~1 Were 
added. The organic layer Was separated and Washed tWice 
With saturated sodium chloride, dried over magnesium 
sulfate, and evaporated to dryness, in vacuo, ?rst With a 
Water aspirator and then With an oil pump. The oily residue 
Was treated With Water (25 ml) and Was again evaporated to 
dryness, in vacuo. This procedure then Was repeated. The 
oily residue (2.80 g) Was then dissolved in methylene 
chloride (100 ml), petroleum ether (250 ml) Was added, and 
the mixture Was stirred overnight. The title compound Was 
isolated by ?ltration and Washed With petroleum ether. Tlc 
(system 1) indicated substantial quantities of 
penta?uorophenol, but no attempt Was made to remove it. 
Yield: 1.72 g (59%). M.p. 156° C. (decomp.). 1H-NMR (250 
MHZ, CDCl3): Due to the limited rotation around the 
secondary amide bond several of the signals Were doubled in 
the ratio 2:1, (indicated in the list by mj. for major and mi. 
for minor). 7.88 ppm (dd,1H,H-6); 7.39 (m,5H,Ph); 7.00 
(dd,1H,H-5); 6.92 (b,1H,BocNH); 6.74 (b,1H,ZNH)-?; 5.19 
(s,2H,Ph—CH3); 4.81 ppm (s, mj., Cyt—CH2—CO—); 
4.62 ppm (s, mi., Cyt—CH2—CO—); 4.23 (s, mi., CONRC 
HZCOZH); 3.98 ppm (s, mj., CONRCHZCOZH); 3.42—3.02 
(unres. m, —CH2CH2— and Water); 1.37 (s,9H,tBu). FAB 
MS: 504 (M+1); 448 (M+1-tBu). 
EXAMPLE 21 
N4-BenZyloxycarbonyl-1-Boc-aeg-cytosine 
penta?uorophenyl ester (13) 
N4-BenZyloxycarbonyl-1-Boc-aeg-cytosine (12, 1.50 g; 
2.98 mmol) and penta?uorophenol (548 mg; 2.98 mmol) 
Was dissolved in DMF (10 ml) Methylene chloride (10 ml) 
Was added, the reaction mixture Was cooled to 00 C. in an ice 
bath, and DCC (676 mg; 3.28 mmol) Was added. The ice 
bath Was removed after 3 min and the mixture Was stirred for 
3 h at ambient temperature. The precipitate Was isolated by 
?ltration and Washed once With methylene chloride. The 
precipitate Was dissolved in boiling dioxane (150 ml) and 
the solution Was cooled to 15° C., Whereby DCU precipi 
tated. The DCU Was removed by ?ltration and the resulting 
?ltrate Was poured into Water (250 ml) at 0° C. The title 
compound Was isolated by ?ltration, Was Washed With Water, 
and dried over sicapent, in vacuo. Yield 1.30 g (65%). 
Analysis for C29H28N5O8F5. Found(calc.); C: 52.63(52.02); 
H: 4.41(4. 22); N: 10.55(10.46). 1H-NMR (250 MHZ; 
DMSO-dG): shoWed essentially the spectrum of the above 
acid, most probably due to hydrolysis of the ester. FAB-MS: 
670 (M+1); 614 (M+1-tBu) 
EXAMPLE 22 
4-Chlorocarboxy-9-chloroacridine 
4-Carboxyacridone (6.25 g; 26.1 mmol), thionyl chloride 
(25 ml), and 4 drops af DMF Were heated gently under a 
How of nitrogen until all solid material had dissolved. The 
solution then Was re?uxed for 40 min. The solution Was 
cooled and excess thionyl chloride Was removed in vacuo. 
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The last traces of thionyl chloride Were removed by 
coevaporation With dry benZene (dried over Na—Pb) tWice. 
The remaining yelloW poWder Was used directly in the next 
reaction. 
EXAMPLE 23 
4-(5 -Methoxycarbonylpentylamidocarbonyl)-9 
chloroacridine 
Methyl 6-aminohexanoate hydrochloride (4.70 g; 25.9 
mmol) Was dissolved in methylene chloride (90 ml), cooled 
to 00 C., triethyl amine (15 ml) Was added, and the resulting 
solution then Was immediately added to the acid chloride 
from above. The roundbottomed ?ask containing the acid 
chloride Was cooled to 0° C. in an ice bath. The mixture Was 
stirred vigorously for 30 min at 0° C. and 3 h at room 
temperature. The resulting mixture Was ?ltered to remove 
the remaining solids, Which Were Washed With methylene 
chloride (20 ml). The red-broWn methylene chloride ?ltrate 
Was subsequently Washed tWice With saturated sodium 
hydrogen carbonate, once With saturated sodium chloride, 
dried over magnesium sulfate, and evaporated to dryness, in 
vacuo. To the resulting oily substance Was added dry ben 
Zene (35 ml) and ligroin (60—80° C., dried over Na—Pb). 
The mixture Was heated to re?ux. Activated carbon and 
celite Were added and mixture Was re?uxed for 3 min. After 
?ltration, the title compound crystallised upon cooling With 
magnetic stirring. It Was isolated by ?ltration and Washed 
With petroleum ether. The product Was stored over solid 
potassium hydroxide. Yield 5.0 g (50%). 
EXAMPLE 24 
4-(5 -Methoxycarbonylpentyl)amidocarbonyl-9-[6‘ 
(4“ -nitrobenZamido)hexylamino]-aminoacridine 
4-(5-Methoxycarbonylpentylamidocarbonyl)-9 
chloroacridine (1.30 g; 3.38 mmol) and phenol (5 g) Were 
heated to 80° C. for 30 min under a How of nitrogen, after 
Which 6-(4‘-nitrobenZamido)-1-hexylamine (897 mg; 3.38 
mmol) Was added. The temperature raised to 120° C. for 2 
h. The reaction mixture Was cooled and methylene chloride 
(80 ml) Was added. The resulting solution Was Washed three 
times With 2N sodium hydroxide (60 ml portions) and once 
With Water, dried over magnesium sulfate, and evaporated to 
dryness, in vacuo. The resulting red oil (1.8 g) Was dissolved 
in methylene chloride (40 ml), cooled to 0° C. Ether (120 
ml) Was added and the resultant solution Was stirred over 
night. This results in a mixture of solid material and an oil. 
The solid Was isolated by ?ltration. The solid and the oil 
Were re-dissolved in methylene chloride (80 ml) and added 
dropWise to cold ether (150 ml). After 20 minutes of stirring, 
the title compound Was isolated by ?ltration in the form of 
orange crystals. The product Was Washed With ether and 
dried in vacuo over potassium hydroxide. Yield 1.60 g 
(77%). M.p. 145—147° C. 
EXAMPLE 25 
4-(5-Carboxypentyl)amidocarbonyl-9-[6‘-(4“ 
nitrobenZamido)hexylamino]-aminoacridine 
4-(5-Methoxycarbonylpentyl)amidocarbonyl-9-[6‘-(4“ 
nitrobenZamido)hexylamino]aminoacridine (503 mg; 0.82 
mmol) Was dissolved in DMF (30 ml), and 2 N sodium 
hydroxide (30 ml) Was added. After stirring for 15 min, 2 N 
hydrochloric acid (35 ml) and Water (50 ml) Were added at 
0° C. After stirring for 30 min, the solution Was decanted, 
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leaving an oily substance Which Was dissolved in boiling 
methanol (150 ml), ?ltered and concentrated to 1/3 volume. 
To the methanol solution Were added ether (125 ml) and 5—6 
drops of HCl in ethanol. The solution Was decanted after 1 
h of stirring at 0° C. The oily substance Was redissolved in 
methanol (25 ml) and precipitated With ether (150 ml). The 
title compound Was isolated as yelloW crystals after stirring 
overnight. Yield 417 mg (80%). M.p. 173° C. (decomp.). 
EXAMPLE 26 
(a) 4-(5-penta?uorophenyloxycarbonylpentyl) 
amidocarbonyl-9-[6-(4“-nitrobenZamido)hexylamino] 
aminoacridine (AcrlOpfp) 
The acid from above (300 mg; 0.480 mmol) Was dissolved 
in DMF (2 ml) and methylene chloride (8 ml) Was added. 
Penta?uorophenol (97 mg; 0.53 mmol), transferred with 2x2 
ml of the methylene chloride, Was added. The resulting 
solution Was cooled to 0° C. after Which DCC (124 mg; 0.60 
mmol) Was subsequently added. The ice bath Was removed 
after 5 minutes and the mixture Was left With stirring 
overnight. The precipitated DCU Was removed by centrifu 
gation and the centrifugate Was evaporated to dryness, in 
vacuo, ?rst by a Water aspirator and then by an oil pump. The 
residue Was dissolved in methylene chloride (20 ml), 
?ltered, and evaporated to dryness, in vacuo. The residue 
Was again dissolved in methylene chloride and petroleum 
ether (150 ml). A 1 ml portion of 5M HCl in ether Was added. 
The solvent Was removed by decanting after 30 min of 
stirring at 0° C. The residual oily substance Was dissolved in 
methylene chloride (100 ml). Petroleum ether (150 ml) Was 
added and the mixture Was left With stirring overnight. The 
next day the yelloW precipitated crystalline material Was 
isolated by ?ltration and Was Washed With copious amounts 
of petroleum ether. Yield, after drying, 300 mg (78%). M.p. 
97.5 ° C. (decomp All samples shoWed satisfactory elemen 
tal analysis, 1H- and 13C-NMR and mass spectra. 
(b) Experimental for the Synthesis of PNA Compounds, cf. 
FIG. 4 
Materials: Boc-Lys (ClZ), benZhydrylamine-copoly 
(styrene-1%-divinylbenZene) resin (BHA resin), and 
p-methylbenZhydrylamine-copoly(styrene-1% 
divinylbenZene) resin (MBHA resin) Were purchased from 
Peninsula Laboratories. Other reagents and solvents Were: 
Biograde tri?uoroacetic acid from Halocarbon Products; 
diisopropylethylamine (99%; Was not further distilled) and 
N-acetylimidaZole (98%) from Aldrich; H2O Was distilled 
tWice; anhydrous HF from Union Carbide; synthesis grade 
N,N-dimethylformamide and analytical grade methylene 
chloride (Was not further distilled) from Merck; HPLC grade 
acetonitrile from Lab-Scan; purum grade anisole, N,N‘ 
dicyclohexylcarbodiimide, and puriss. grade 2,2,2 
tri?uoroethanol from Fluka. 
(c) General Methods and Remarks 
Except Where otherWise stated, the folloWing applies. The 
PNA compounds Were syntheZised by the stepWise solid 
phase approach (Merri?eld, J. Am. Chem. Soc, 1963, 85, 
2149) employing conventional peptide chemistry utiliZing 
the TFA-labile tert-butyloxycarbonyl (Boc) group for “tem 
porary” N-protection (Merri?eld, J. Am. Chem. Soc., 1964, 
86, 304) and the more acid-stable benZyloxycarbonyl (Z) 
and 2-chlorobenZyloxycarbonyl (ClZ) groups for “perma 
nent” side chain protection. To obtain C-terminal amides, the 
PNAs Were assembled onto the HF-labile BHA or MBHA 
resins (the MBHA resin has increased susceptibility to the 
?nal HF cleavage relative to the unsubstituted BHA resin 
(Matsueda, et al., Peptides, 1981, 2, 45). All reactions 
(except HF reactions) Were carried out in manually operated 
standard solid-phase reaction vessels ?tted With a coarse 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
30 
glass frit (Merri?eld, et al., Biochemistry, 1982, 21, 5020). 
The quantitative ninhydrin reaction (Kaiser test), originally 
developed by Merri?eld and co-Workers (Sarin, et al.,Anal. 
Biochem., 1981, 117, 147) for peptides containing “normal” 
amino acids, Was successfully applied (see Table I—III) using 
the “normally” employed effective extinction coef?cient 
e=15000 M_1cm_1 for all residues to determine the com 
pleteness of the individual couplings as Well as to measure 
the number of groWing peptide chains. The theoretical 
substitution Sn_1 upon coupling of residue number n 
(assuming both complete deprotection and coupling as Well 
as neither chain termination nor loss of PNA chains during 
the synthetic cycle) is calculated from the equation: 
Where AMW is the gain in molecular Weight ([AMW]=g/ 
mol) and Sn_1 is the theoretical substitution upon coupling 
of the preceding residue n—1 ([S]=mmol/g). The estimated 
value (%) on the extent of an individual coupling is calcu 
lated relative to the measured substitution (unless S Was not 
determined) and include correction for the number of 
remaining free amino groups folloWing the previous cycle. 
HF reactions Were carried out in a Dia?on HF apparatus 
from Toho Kasei (Osaka, Japan). Vydac C18 (5 pm, 0.46><25 
cm and 5 pm, 10x25 cm) reverse-phase columns, respec 
tively Were used for analytical and semi-preparative HPLC 
on an SP8000 instrument. Buffer AWas 5 vol % acetonitrile 
in Water containing 445 pl tri?uoroacetic acid per liter, and 
buffer B Was 60 vol % acetonitrile in Water containing 390 
pl tri?uoroacetic acid per liter. The linear gradient Was 
0—100% of buffer B in 30 min, ?oW rates 1.2 ml/min 
(analytical) and 5 ml/min (semi-preparative). The eluents 
Were monitored at 215 nm (analytical) and 230 nm (semi 
preparative). Molecular Weights of the PNAs Were deter 
mined by 252Cf plasma desorption time-of-?ight mass spec 
trometry from the mean of the most abundant isotopes. 
EXAMPLE 27 
Solid-Phase Synthesis of Acrl-[Taeghs-NH2 and 
Shorter Derivatives 
(a) StepWise Assembly of Boc-[Taeg]15-BHA Resin 
The synthesis Was initiated on 100 mg of presWollen and 
neutraliZed BHA resin (determined by the quantitative nin 
hydrin reaction to contain 0.57 mmol NHZ/g) employing 
single couplings (“Synthetic Protocol 1”) using 3.2 equiva 
lents of BocTaeg-OPfp in about 33% DMF/CH2Cl2. The 
individual coupling reactions Were carried out by shaking 
for at least 12 h in a manually operated 6 ml standard 
solid-phase reaction vessel and unreacted amino groups 
Were blocked by acetylation at selected stages of the syn 
thesis. The progress of chain elongation Was monitored at 
several stages by the quantitative ninhydrin reaction (see 
Table I). Portions of protected Boc-[Taeg]5-BHA, Boc 
[Taeg]1O-BHA, and Boc-[Taeg]15-BHA resins Were taken 
out after assembling 5, 10, and 15 residues, respectively. 










































